Works matching IS 01676997 AND DT 2021 AND VI 39 AND IP 2

Results: 31
    1
    2

    Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 564, doi. 10.1007/s10637-020-00999-y
    By:
    • Takamizawa, Shigemasa;
    • Honma, Yoshitaka;
    • Murakami, Naoya;
    • Mori, Taisuke;
    • Oka, Hiroki;
    • Yamamoto, Shun;
    • Kashihara, Tairo;
    • Ito, Kimiteru;
    • Kubo, Yuko;
    • Ikeda, Atsuo;
    • Matsumoto, Fumihiko;
    • Omura, Go;
    • Kobayashi, Kenya;
    • Itami, Jun;
    • Kato, Ken;
    • Yoshimoto, Seiichi
    Publication type:
    Article
    3

    A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 509, doi. 10.1007/s10637-020-00995-2
    By:
    • Yam, Clinton;
    • Rauch, Gaiane M.;
    • Rahman, Tanbin;
    • Karuturi, Meghan;
    • Ravenberg, Elizabeth;
    • White, Jason;
    • Clayborn, Alyson;
    • McCarthy, Pamela;
    • Abouharb, Sausan;
    • Lim, Bora;
    • Litton, Jennifer K.;
    • Ramirez, David L.;
    • Saleem, Sadia;
    • Stec, James;
    • Symmans, W. Fraser;
    • Huo, Lei;
    • Damodaran, Senthil;
    • Sun, Ryan;
    • Moulder, Stacy L.
    Publication type:
    Article
    4
    5
    6

    Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 530, doi. 10.1007/s10637-020-01031-z
    By:
    • Otani, Sakiko;
    • Sasaki, Jiichiro;
    • Nakahara, Yoshiro;
    • Fukui, Tomoya;
    • Igawa, Satoshi;
    • Naoki, Katsuhiko;
    • Bessho, Akihiro;
    • Hosokawa, Shinobu;
    • Fukamatsu, Nobuaki;
    • Nakamura, Yukiko;
    • Kasai, Takashi;
    • Sugiyama, Tomohide;
    • Tokito, Takaaki;
    • Seki, Nobuhiko;
    • Hamada, Akinobu;
    • Okamoto, Hiroaki;
    • Masuda, Noriyuki
    Publication type:
    Article
    7

    A decision process for drug discovery in retinoblastoma.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 426, doi. 10.1007/s10637-020-01030-0
    By:
    • Cancela, María Belen;
    • Zugbi, Santiago;
    • Winter, Ursula;
    • Martinez, Ana Laura;
    • Sampor, Claudia;
    • Sgroi, Mariana;
    • Francis, Jasmine H.;
    • Garippa, Ralph;
    • Abramson, David H.;
    • Chantada, Guillermo;
    • Schaiquevich, Paula
    Publication type:
    Article
    8
    9
    10
    11
    12

    A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 605, doi. 10.1007/s10637-020-01022-0
    By:
    • Saito, Kei;
    • Nakai, Yousuke;
    • Takahara, Naminatsu;
    • Ishigaki, Kazunaga;
    • Suzuki, Yukari;
    • Inokuma, Akiyuki;
    • Noguchi, Kensaku;
    • Kanai, Sachiko;
    • Sato, Tatsuya;
    • Hakuta, Ryunosuke;
    • Saito, Tomotaka;
    • Hamada, Tsuyoshi;
    • Mizuno, Suguru;
    • Kogure, Hirofumi;
    • Ijichi, Hideaki;
    • Tateishi, Keisuke;
    • Koike, Kazuhiko
    Publication type:
    Article
    13
    14

    Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 400, doi. 10.1007/s10637-020-01020-2
    By:
    • Nakamura-Bencomo, Sayuri;
    • Gutierrez, Denisse A.;
    • Robles-Escajeda, Elisa;
    • Iglesias-Figueroa, Blanca;
    • Siqueiros-Cendón, Tania S.;
    • Espinoza-Sánchez, Edward A.;
    • Arévalo-Gallegos, Sigifredo;
    • Aguilera, Renato J.;
    • Rascón-Cruz, Quintín;
    • Varela-Ramirez, Armando
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22

    A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 477, doi. 10.1007/s10637-020-01010-4
    By:
    • Yang, Jin-Ji;
    • Fang, Jian;
    • Shu, Yong-Qian;
    • Chang, Jian-Hua;
    • Chen, Gong-Yan;
    • He, Jian Xing;
    • Li, Wei;
    • Liu, Xiao-Qing;
    • Yang, Nong;
    • Zhou, Caicun;
    • Huang, Jian An;
    • Frigault, Melanie M.;
    • Hartmaier, Ryan;
    • Ahmed, Ghada F.;
    • Egile, Coumaran;
    • Morgan, Shethah;
    • Verheijen, Remy B.;
    • Mellemgaard, Anders;
    • Yang, Liu;
    • Wu, Yi-Long
    Publication type:
    Article
    23
    24
    25
    26
    27

    Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 571, doi. 10.1007/s10637-020-01005-1
    By:
    • Kodama, Hiroaki;
    • Wakuda, Kazushige;
    • Yabe, Michitoshi;
    • Nishioka, Naoya;
    • Miyawaki, Eriko;
    • Miyawaki, Taichi;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Endo, Masahiro;
    • Takahashi, Toshiaki
    Publication type:
    Article
    28
    29
    30
    31